Dopaminergic D2 receptor knockout mouse: An animal model of prolactinoma
Dopamine receptor type 2 (D2R) knockout mice (KO) have chronic hyperprolactinemia, pituitary hyperplasia, and a moderate decrease in MSH content. They are also growth retarded evidencing an alteration in the GH-IGF-I axis. In D2R KO, lactotropes do not show dense secretory granules but degranulated...
Guardado en:
| Autor principal: | |
|---|---|
| Otros Autores: | , , , , , , , |
| Formato: | Capítulo de libro |
| Lenguaje: | Inglés |
| Publicado: |
2006
|
| Materias: | |
| Acceso en línea: | Registro en Scopus DOI Handle Registro en la Biblioteca Digital |
| Aporte de: | Registro referencial: Solicitar el recurso aquí |
| LEADER | 14649caa a22013697a 4500 | ||
|---|---|---|---|
| 001 | PAPER-21789 | ||
| 003 | AR-BaUEN | ||
| 005 | 20230518205316.0 | ||
| 008 | 190411s2006 xx ||||fo|||| 00| 0 eng|d | ||
| 024 | 7 | |2 scopus |a 2-s2.0-33745795815 | |
| 024 | 7 | |2 cas |a vasculotropin A, 489395-96-2; Receptors, Dopamine D2; Vascular Endothelial Growth Factor A; vascular endothelial growth factor A, mouse | |
| 040 | |a Scopus |b spa |c AR-BaUEN |d AR-BaUEN | ||
| 100 | 1 | |a Cristina, C. | |
| 245 | 1 | 0 | |a Dopaminergic D2 receptor knockout mouse: An animal model of prolactinoma |
| 260 | |c 2006 | ||
| 270 | 1 | 0 | |m Becú-Villalobos, D.; Instituto de Biología Y Medicina Experimental, CONICET, Vuelta de Obligado 2490, 1428 Buenos Aires, Argentina; email: dbecu@dna.uba.ar |
| 506 | |2 openaire |e Política editorial | ||
| 504 | |a Ezzat, S., Zheng, L., Zhu, X.F., Wu, G.E., Asa, S.L., Targeted expression of a human pituitary tumor-derived isoform of FGF receptor-4 recapitulates pituitary tumorigenesis (2002) J Clin Invest, 109, pp. 69-78 | ||
| 504 | |a McAndrew, J., Paterson, A.J., Asa, S.L., McCarthy, K.J., Kudlow, J.E., Targeting of transforming growth factor-alpha expression to pituitary lactotrophs in transgenic mice results in selective lactotroph proliferation and adenomas (1995) Endocrinology, 136, pp. 4479-4488 | ||
| 504 | |a Borrelli, E., Sawchenko, P.E., Evans, R.M., Pituitary hyperplasia induced by ectopic expression of nerve growth factor (1992) Proc Natl Acad Sci, 89, pp. 2764-2768. , USA | ||
| 504 | |a Fedele, M., Battista, S., Kenyon, L., Baldassarre, G., Fidanza, V., Klein-Szanto, A.J., Parlow, A.F., Fusco, A., Overexpression of the HMGA2 gene in transgenic mice leads to the onset of pituitary adenomas (2002) Oncogene, 21, pp. 3190-3198 | ||
| 504 | |a Perumal, P., Vrontakis, M.E., Transgenic mice over-expressing galanin exhibit pituitary adenomas and increased secretion of galanin, prolactin and growth hormone (2003) J Endocrinol, 179, pp. 145-154 | ||
| 504 | |a Cai, A., Hayes, J.D., Patel, N., Hyde, J.F., Targeted overexpression of galanin in lactotrophs of transgenic mice induces hyperprolactinemia and pituitary hyperplasia (1999) Endocrinology, 140, pp. 4955-4964 | ||
| 504 | |a Ikeda, H., Yoshimoto, T., Shida, N., Miyoshi, I., Nakayama, K., Nakayama, K., Oshima, M., Taketo, M.M., Morphologic and molecular analysis of estrogen-induced pituitary tumorigenesis in targeted disruption of transforming growth factor-beta receptor type II and/or p27 mice (2001) Endocrine, 16, pp. 55-65 | ||
| 504 | |a Schuff, K.G., Hentges, S.T., Kelly, M.A., Binart, N., Kelly, P.A., Iuvone, P.M., Asa, S.L., Low, M.J., Lack of prolactin receptor signaling in mice results in lactotroph proliferation and prolactinomas by dopamine-dependent and -independent mechanisms (2002) J Clin Invest, 110, pp. 973-981 | ||
| 504 | |a Asa, S.L., Kelly, M.A., Grandy, D.K., Low, M.J., Pituitary lactotroph adenomas develop after prolonged lactotroph hyperplasia in dopamine D2 receptor-deficient mice (1999) Endocrinology, 140, pp. 5348-5355 | ||
| 504 | |a Kelly, M.A., Rubinstein, M., Asa, S.L., Zhang, G., Saez, C., Bunzow, J.R., Allen, R.G., Low, M.J., Pituitary lactotroph hyperplasia and chronic hyperprolactinemia in dopamine D2 receptor-deficient mice (1997) Neuron, 19, pp. 103-113 | ||
| 504 | |a Kelly, M.A., Rubinstein, M., Phillips, T.J., Lessovn, C.N., Burkhart-Kasch, S., Zhang, G., Bunzow, J.R., Low, M.J., Locomotor activity in D2 dopamine receptor-deficient mice is determined by gene dosage, genetic background, and developmental adaptations (1998) J Neurosci, 18, pp. 3470-3479 | ||
| 504 | |a Diaz-Torga, G., Feierstein, C., Libertun, C., Gelman, D., Kelly, M.A., Low, M.J., Rubinstein, M., Becu-Villalobos, D., Disruption of the D2 dopamine receptor alters GH and IGF-I secretion and causes dwarfism in male mice (2002) Endocrinology, 143, pp. 1270-1279 | ||
| 504 | |a Hentges, S.T., Low, M.J., Ovarian dependence for pituitary tumorigenesis in D2 dopamine receptor-deficient mice (2002) Endocrinology, 143, pp. 4536-4543 | ||
| 504 | |a Basu, S., Nagy, J.A., Pal, S., Vasile, E., Eckelhoefer, I.A., Bliss, V.S., Manseau, E.J., Mukhopadhyay, D., The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor (2001) Nat Med, 7, pp. 569-574 | ||
| 504 | |a Chakroborty, D., Sarkar, C., Mitra, R.B., Banerjee, S., Dasgupta, P.S., Basu, S., Depleted dopamine in gastric cancer tissues: Dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis (2004) Clin Cancer Res, 10, pp. 4349-4356 | ||
| 504 | |a Banerjee, S.K., Sarkar, D.K., Weston, A.P., De, A., Campbell, D.R., Over expression of vascular endothelial growth factor and its receptor during the development of estrogen-induced rat pituitary tumors may mediate estrogen-initiated tumor angiogenesis (1997) Carcinogenesis, 18, pp. 1155-1161 | ||
| 504 | |a Onofri, C., Carbia, N.A., Schaaf, L., Feirer, M., Lohrer, P., Stummer, W., Berner, S., Arzt, E., Estradiol stimulates vascular endothelial growth factor and interleukin-6 in human lactotroph and lactosomatotroph pituitary adenomas (2004) Exp Clin Endocrinol Diabetes, 112, pp. 18-23 | ||
| 504 | |a Ferrara, N., Gerber, H., LeCouter, J., The biology of VEGF and its receptors (2003) Nat Med, 9, pp. 669-676 | ||
| 504 | |a Ferrara, N., Davis-Smyth, T., The biology of vascular endothelial growth factor (1997) Endocr Rev, 18, pp. 4-25 | ||
| 504 | |a Teunis, M.A., Kavelaars, A., Voest, E., Bakker, J.M., Ellenbroek, B.A., Cools, A.R., Heijnen, C.J., Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system (2002) FASEB J, 16, pp. 1465-1467 | ||
| 504 | |a Cristina, C., Diaz-Torga, G., Baldi, A., Gongora, A., Rubinstein, M., Low, M.J., Becu-Villalobos, D., Increased pituitary vascular endothelial growth factor-A in dopaminergic D2 receptor knockout female mice (2005) Endocrinology, 146, pp. 2952-2962 | ||
| 504 | |a Ochoa, A.L., Mitchner, N.A., Paynter, C.D., Morris, R.E., Ben Jonathan, N., Vascular endothelial growth factor in the rat pituitary: Differential distribution and regulation by estrogen (2000) J Endocrinol, 165, pp. 483-492 | ||
| 504 | |a Vidal, S., Kovacs, K., Cohen, S.M., Stefaneanu, L., Lloyd, R.V., Scheithauer, B.W., Localization of vascular endothelial growth factor in non tumorous human pituitaries (1999) Endocr Pathol, 10, pp. 109-122 | ||
| 504 | |a Gospodarowicz, D., Abraham, J.A., Schilling, J., Isolation and characterization of a vascular endothelial mitogen produced by pituitary-derived folliculostellate cells (1989) Proc Natl Acad Sci, 86, pp. 7311-7315. , USA | ||
| 504 | |a Fan, L., Iseki, S., Immunohistochemical localization of vascular endothelial growth factor in the endocrine glands of the rat (1998) Arch Histol Cytol, 61, pp. 17-28 | ||
| 504 | |a Stojilkovic, S.S., A novel view of the function of pituitary folliculo-stellate cell network (2001) Trends Endocrinol Metab, 12, pp. 378-380 | ||
| 504 | |a Gloddek, J., Pagotto, U., Paez, P.M., Arzt, E., Stalla, G.K., Renner, U., Pituitary adenylate cyclase-activating polypeptide, interleukin-6 and glucocorticoids regulate the release of vascular endothelial growth factor in pituitary folliculostellate cells (1999) J Endocrinol, 160, pp. 483-490 | ||
| 504 | |a Joseph, F., Younis, N., Haydon, G., Adams, D.H., Wynne, S., Gillet, M.B., Maurice, Y.M., Jones, I.R., Peliosis of the spleen with massive recurrent haemorrhagic ascites, despite splenectomy, and associated with elevated levels of vascular endothelial growth factor (2004) Eur J Gastroenterol Hepatol, 16, pp. 1401-1406 | ||
| 504 | |a Park, Y.N., Kim, Y.B., Yang, K.M., Park, C., Increased expression of vascular endothelial growth factor and angiogenesis in the early stage of multistep hepatocarcinogenesis (2000) Arch Pathol Lab Med, 124, pp. 1061-1065 | ||
| 504 | |a Wong, A.K., Alfert, M., Castrillon, D.H., Shen, Q., Holash, J., Yancopoulos, G.D., Chin, L., Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome (2001) Proc Natl Acad Sci, 98, pp. 7481-7486. , USA | ||
| 504 | |a Vidal, S., Lloyd, R.V., Moya, L., Scheithauer, B.W., Kovacs, K., Expression and distribution of vascular endothelial growth factor receptor Flk-1 in the rat pituitary (2002) J Histochem Cytochem, 50, pp. 533-540 | ||
| 504 | |a Yu, R., Ren, S.-G., Horwitz, G.A., Wang, Z., Melmed, S., Pituitary tumor transforming gene (PTTG) regulates placental JEG-3 cell division and survival: Evidence from live cell imaging (2000) Mol Endocrinol, 14, pp. 1137-1146 | ||
| 504 | |a Kuchenbauer, F., Theodoropoulou, M., Hopfner, U., Stalla, J., Renner, U., Tonn, J.C., Low, M.J., Paez-Pereda, M., Laminin inhibits lactotroph proliferation and is reduced in early prolactinoma development (2003) Mol Cell Endocrinol, 207, pp. 13-20 | ||
| 504 | |a Cristina, C., Achaval-Zaia, R., Baldi, A., Low, M.J., Rubinstein, M., Diaz-Torga, G., Becu-Villalobos, D., Factores de crecimiento en la hiperplasia hipofisaria de ratones hembra deficientes en el receptor dopaminérgico tipo 2 (2000) Medicina, 62, p. 469 | ||
| 504 | |a Ezzat, S., Zheng, L., Asa, S.L., Pituitary tumor-derived fibroblast growth factor receptor 4 isoform disrupts neural cell-adhesion molecule/N-cadherin signaling to diminish cell adhesiveness: A mechanism underlying pituitary neoplasia (2004) Mol Endocrinol, 18, pp. 2543-2552 | ||
| 504 | |a Bergsland, E.K., Update on clinical trials targeting vascular endothelial growth factor in cancer (2004) Am J Health Syst Pharm, 61, pp. S12-S20 | ||
| 504 | |a Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Kabbinavar, F., Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer (2004) N Engl J Med, 350, pp. 2335-2342 | ||
| 504 | |a Yamada, S., Takada, K., Angiogenesis in pituitary adenomas (2003) Microsc Res Tech, 60, pp. 236-243 | ||
| 504 | |a Lloyd, R.V., Vidal, S., Horvath, E., Kovacs, K., Scheithauer, B., Angiogenesis in normal and neoplastic pituitary tissues (2003) Microsc Res Tech, 60, pp. 244-250 | ||
| 520 | 3 | |a Dopamine receptor type 2 (D2R) knockout mice (KO) have chronic hyperprolactinemia, pituitary hyperplasia, and a moderate decrease in MSH content. They are also growth retarded evidencing an alteration in the GH-IGF-I axis. In D2R KO, lactotropes do not show dense secretory granules but degranulated cells and fewer somatotropes, gonadotropes and thyrotropes. Prolactin levels are always higher in female than in male knockouts, and in accordance, pituitary hyperplasia is observed at 8 months only in females. After 16 months of age, highly vascularized adenomas develop, especially in females. Prominent vascular channels in the hyperplastic and adenomatous pituitaries, as well as extravasated red blood cells not contained in capillaries is also a common finding. Prolactin is not the factor that enhances the hyperplastic phenotype in females while estrogen is a permissive factor. VEGF-A expression is increased in pituitaries from D2R KO. VEGF-A is expressed in follicle stellate cells. Because D2R receptors are found in lactotropes and not in follicle stellate cells, it may be inferred that a paracrine-derived factor from lactotropes is acting on follicle stellate cells to increase VEGF-A expression. VEGF-A does not induce pituitary cell proliferation, even though it enhances prolactin secretion. But it may act on adjacent endothelial cells and participate in the angiogenic process that increases the availability of different growth factors and mitogens. The D2R knockout mouse represents a unique animal model to study dopamine-resistant prolactinomas, and VEGF-A may be an alternative therapeutic target in this pathology. Copyright © 2006 S. Karger AG. |l eng | |
| 593 | |a Instituto de Biología Y Medicina Experimental-CONICET, Buenos Aires, Argentina | ||
| 593 | |a Instituto de Investigaciones en Ingeniería Genética Y Biología Molecular, CONICET and University of Buenos Aires, Buenos Aires, Argentina | ||
| 593 | |a Vollum Institute, Oregon Health and Science University, Portland, OR, United States | ||
| 593 | |a Instituto de Biología Y Medicina Experimental, CONICET, Vuelta de Obligado 2490, 1428 Buenos Aires, Argentina | ||
| 690 | 1 | 0 | |a DOPAMINE 2 RECEPTOR |
| 690 | 1 | 0 | |a VASCULAR ENDOTHELIAL GROWTH FACTOR A, MOUSE |
| 690 | 1 | 0 | |a VASCULOTROPIN A |
| 690 | 1 | 0 | |a ANIMAL |
| 690 | 1 | 0 | |a CELL ADHESION |
| 690 | 1 | 0 | |a CONFERENCE PAPER |
| 690 | 1 | 0 | |a DISEASE MODEL |
| 690 | 1 | 0 | |a DRUG RESISTANCE |
| 690 | 1 | 0 | |a FEMALE |
| 690 | 1 | 0 | |a GENETICS |
| 690 | 1 | 0 | |a HYPOPHYSIS |
| 690 | 1 | 0 | |a HYPOPHYSIS TUMOR |
| 690 | 1 | 0 | |a MALE |
| 690 | 1 | 0 | |a MOUSE |
| 690 | 1 | 0 | |a MOUSE MUTANT |
| 690 | 1 | 0 | |a NEOVASCULARIZATION (PATHOLOGY) |
| 690 | 1 | 0 | |a PATHOLOGY |
| 690 | 1 | 0 | |a PELIOSIS HEPATIS |
| 690 | 1 | 0 | |a PHYSIOLOGY |
| 690 | 1 | 0 | |a PROLACTINOMA |
| 690 | 1 | 0 | |a SEXUAL DEVELOPMENT |
| 690 | 1 | 0 | |a VASCULARIZATION |
| 690 | 1 | 0 | |a ANIMALS |
| 690 | 1 | 0 | |a CELL ADHESION |
| 690 | 1 | 0 | |a DISEASE MODELS, ANIMAL |
| 690 | 1 | 0 | |a DRUG RESISTANCE, NEOPLASM |
| 690 | 1 | 0 | |a FEMALE |
| 690 | 1 | 0 | |a MALE |
| 690 | 1 | 0 | |a MICE |
| 690 | 1 | 0 | |a MICE, KNOCKOUT |
| 690 | 1 | 0 | |a NEOVASCULARIZATION, PATHOLOGIC |
| 690 | 1 | 0 | |a PELIOSIS HEPATIS |
| 690 | 1 | 0 | |a PITUITARY GLAND |
| 690 | 1 | 0 | |a PITUITARY NEOPLASMS |
| 690 | 1 | 0 | |a PROLACTINOMA |
| 690 | 1 | 0 | |a RECEPTORS, DOPAMINE D2 |
| 690 | 1 | 0 | |a SEX CHARACTERISTICS |
| 690 | 1 | 0 | |a VASCULAR ENDOTHELIAL GROWTH FACTOR A |
| 651 | 4 | |a HYPERPLASIA | |
| 651 | 4 | |a HYPERPLASIA | |
| 700 | 1 | |a García-Tornadú, I. | |
| 700 | 1 | |a Díaz-Torga, G. | |
| 700 | 1 | |a Rubinstein, M. | |
| 700 | 1 | |a Low, M.J. | |
| 700 | 1 | |a Becú-Villalobos, D. | |
| 700 | 1 | |a Arzt E. | |
| 700 | 1 | |a Guitelman M | |
| 700 | 1 | |a Bronstein M. | |
| 773 | 0 | |d 2006 |g v. 35 |h pp. 50-63 |p Front. Horm. Res. |x 03013073 |z 3805581556 |z 9783805581554 |t Frontiers of Hormone Research | |
| 856 | 4 | 1 | |u https://www.scopus.com/inward/record.uri?eid=2-s2.0-33745795815&doi=10.1159%2f000094308&partnerID=40&md5=01e59ca72dea18503f2517b929845220 |y Registro en Scopus |
| 856 | 4 | 0 | |u https://doi.org/10.1159/000094308 |y DOI |
| 856 | 4 | 0 | |u https://hdl.handle.net/20.500.12110/paper_03013073_v35_n_p50_Cristina |y Handle |
| 856 | 4 | 0 | |u https://bibliotecadigital.exactas.uba.ar/collection/paper/document/paper_03013073_v35_n_p50_Cristina |y Registro en la Biblioteca Digital |
| 961 | |a paper_03013073_v35_n_p50_Cristina |b paper |c PE | ||
| 962 | |a info:eu-repo/semantics/article |a info:ar-repo/semantics/artículo |b info:eu-repo/semantics/publishedVersion | ||
| 999 | |c 82742 | ||